nanogen - 500 Beiträge pro Seite

[frank55]

Nanogen/BD Joint Venture Awarded Its First U.S. Patent


SAN DIEGO, Jun 4, 2001 /PRNewswire via COMTEX/ -- Nanogen, Inc.,
("Nanogen")(Nasdaq: NGEN) and BD (Becton, Dickinson and Company) (NYSE: BDX)
announced that on May 29, 2001, their joint venture was awarded its first United
States Patent relating to technology the parties developed together. The patent,
U.S. Patent No. 6,238,868 (the "`868 patent"), is entitled "Multiplex
Amplification And Separation Of Nucleic Acid Sequences Using Ligation-Dependent
Strand Displacement Amplification and Bioelectronic Chip Technology."

The `868 patent claims cover a kit and methods employing ligation-dependent
strand displacement amplification ("SDA") on a bioelectronic chip that
facilitate optimization of multiplex amplification, detection and analysis of
nucleic acid sequences. SDA is BD`s proprietary isothermal amplification
technique, which is compatible with Nanogen`s unified
amplification-hybridization detection system on one bioelectronic chip. This
creates a combination of technologies designed to increase speed of analysis.

Nanogen`s electronic technology is uniquely adapted for this application since
the amplification primers can be immobilized on individual sets of microarray
sites by electronic addressing. This means amplification occurs on individual
sets of pads, resulting in spatially separated reactions. The advantages of
these techniques include the ability to perform multiple reactions
simultaneously and in the same reaction mix, but with a greatly reduced risk of
interaction among oligonucleotide reagents. Multiplex amplification reactions
with conventional technologies are difficult to optimize because the
oligonucleotides can freely interact with each other, resulting in undesirable
side reactions. The claimed technology is designed to increase the level of
automation and ease of use of the NanoChip(TM) system, especially for future
diagnostic applications.

Kieran Gallahue, president of Nanogen, commented: "Amplification in most genetic
analyses is a costly and sensitive step. The `868 patent describes the use of
on-chip strand displacement amplification on Nanogen`s NanoChip(TM) cartridge,
potentially simplifying the amplification and detection process and lowering
costs. The issuance of the patent demonstrates the potential for leveraging
electronics in the development of sample-to-answer systems and is a significant
step in our drive for leadership in clinical molecular diagnostics."

Nanogen / BD Joint Venture

Nanogen and BD entered into a joint venture in October 1997, known as The
Nanogen / Becton Dickinson Partnership, to develop and commercialize products
primarily in the field of in vitro nucleic acid-based diagnostics and monitoring
technologies in the field of infectious diseases. Nanogen and BD contributed to
the joint venture licenses to certain intellectual property owned by each party,
including BD`s SDA technology and Nanogen`s bioelectronic chip technology.

In September 2000, Nanogen and BD restructured their joint venture to permit the
partners to commercialize certain discoveries from the joint venture`s
technology and allow each partner to collaborate with third parties to develop
and commercialize products in the field of infectious diseases. Nanogen obtained
a license to certain joint venture technologies to commercialize products in the
field of infectious diseases. BD also expanded the field of use for Nanogen`s
SDA license outside of the joint venture to not only include in vitro human
genetic testing and in vitro cancer diagnostics, but also in vitro testing of
environmental, agricultural and veterinary samples.

Nanogen, Inc.

Nanogen markets its NanoChip(TM) Molecular Biology Workstation system to
scientists and genomics laboratories, setting new standards for SNP scoring. In
addition, Nanogen is developing a series of electronics-based products to help
researchers and clinical healthcare providers accelerate their practical
understanding and use of genomic information. The products introduced and under
development are intended to provide quick and accurate analysis of DNA, RNA and
proteins, and may eventually "bridge" the gap between the research and clinical
settings. The Nanogen system is intended for research use only and not for use
in diagnostic procedures. For additional information, please visit Nanogen`s web
site at www.nanogen.com

Becton, Dickinson and Company

BD is a medical technology company that manufactures and sells a broad range of
supplies, devices and systems for use by healthcare professionals, medical
research institutions, industry and the general public. For additional
information, visit the BD web site at www.bd.com.

This press release contains forward-looking statements that are subject to risks
and uncertainties that could cause actual results to differ materially from
those set forth in the forward-looking statements, including whether Nanogen`s
NanoChip(TM) system can be successfully commercialized, whether products under
development can be successfully developed and commercialized, whether the
patented inventions can be successfully incorporated into commercial products,
whether results reported by our customers or partners can be identically
replicated, and whether Nanogen`s collaborations will continue to be funded.
Other risks and uncertainties are discussed under the caption "Factors That May
Affect Results" and elsewhere in Nanogen`s Form 10-K for the year ended December
31, 2000 filed with the Securities and Exchange Commission as well as BD`s
filings with the Securities and Exchange Commission. These forward-looking
statements speak only as of the date hereof. Nanogen and BD disclaim any intent
or obligation to update these forward-looking statements.

[frank55]

SAN DIEGO, am 4. Juni 2001/PRNewswire durch COMTEX/-Nanogen, Inc. ("Nanogen") (Nasdaq: NGEN) und BD (Becton, Dickinson und Firma) (NYSE: BDX) kündigte an, dass am 29. Mai 2001 ihr Gemeinschaftsunternehmen sein erstes USA Patent in Zusammenhang mit Technologie die Parteien entwickelt zusammen zuerkannt wurde. Das Patent, US-amerikanische Offene(patentierte) No 6,238,868 (der " ` 868 offen(patentiert) "), wird " Mehrfacherweiterung berechtigt, und Trennung von Nucleic Sauren Reihenfolgen, die Ligation-abhängigen Gebrauchen, läßt Verlagerungs-Erweiterung und Bioelectronic-Span-Technologie Stranden. "

Die ` 868 offenen(patentierten) Ansprüche bedecken ein Werkzeug und Methoden, die ligation-abhängige Ufer-Verlagerungs-Erweiterung ("SDA") auf einem Bioelectronic-Span beschäftigen, die Optimierung der Mehrfacherweiterung, Aufdeckung und Analyse von nucleic sauren Reihenfolgen erleichtern. SDA ist BD ` s isothermische Eigentumserweiterungs-Technik, die mit Nanogen ` s vereinigtes Aufdeckungs-System der Erweiterung-hybridization auf einem Bioelectronic-Span vereinbar ist. Das schafft eine Verbindung von Technologien

[Maxxtro]

Hallo all..

Ich finds ja ganz gut wenn sich einer die Mühe macht und Adhocs unserer NGEN per Übersetzungsmaschine übersetzen lässt.Allerdings verstehe ich trotz meiner nicht vorhandenen Englishkenntnisse das Original doch besser als die Übersetzung.LOL..

Neue Adhoc über NGEN.

Nanogen Is Awarded U.S. Patent for DNA Fingerprinting
TUESDAY, JUNE 12, 2001 7:00 AM
- PRNewswire

SAN DIEGO, Jun 12, 2001 /PRNewswire via COMTEX/ -- Nanogen, Inc. (Nasdaq:NGEN) announced that today it has been awarded an additional United States Patent relating to methods for using its electronic microarray technology for DNA fingerprinting. U.S. Patent No. 6,245,508, entitled "Method of Fingerprinting Utilizing an Electronically Addressable Array" (the "`508 patent"), is the twenty-fourth U.S. patent issued to the Company. This patent further illustrates the flexibility and applicability of Nanogen`s electronic microarray technology to enhancing molecular biological procedures. This is Nanogen`s fifth patent to issue in the last three months.

The `508 patent claims cover methods for DNA fingerprinting using electronically addressable arrays. The claims describe improved methods for DNA fingerprinting and analysis by applying electronic stringency control to manipulate DNA samples and to electronically discriminate between varying lengths of DNA fragments. This information can be useful in instances where the source of DNA is to be determined, such as in paternity and forensic analyses.

Ron Sosnowski, Ph.D., Nanogen`s Director of Molecular Biology and co-inventor on the `508 patent, stated, "The claims of the `508 describe the direct use of an electric field to discriminate DNA fragments according to length. This is a further demonstration of the unique capability of electric fields in controlling DNA hybridization processes."

Kieran T. Gallahue, President of Nanogen, commented, "We are very pleased with the rapid expansion of our patent portfolio. The `508 patent represents another example of an important application that is enhanced and improved through the integration of electronic control. Nanogen continues to invest in technology developments that will integrate the power of electronics with customer-valued applications."

Nanogen markets its NanoChip(TM) Molecular Biology Workstation system to scientists and genomics laboratories, setting new standards for SNP scoring. In addition, Nanogen is developing a series of electronics-based products to help researchers and clinical healthcare providers accelerate their practical understanding and use of genomic information. The products introduced and under development are intended to provide quick and accurate analysis of DNA, RNA and proteins, and may eventually "bridge" the gap between the research and clinical settings. The Nanogen system is intended for research use only and not for use in diagnostic procedures. For additional information please visit Nanogen`s web site at www.nanogen.com.

This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether the Company`s NanoChip(TM) system can be successfully commercialized, whether products under development can be successfully developed and commercialized, whether the patented inventions can be successfully incorporated into commercial products, whether results reported by our customers or partners can be identically replicated, whether the Company`s collaborations will continue to be funded, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in the Company`s Form 10-K for the year ended December 31, 2000 filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.

MAKE YOUR OPINION COUNT - Click Here
http://tbutton.prnewswire.com/prn/11690X24609187

SOURCE Nanogen, Inc

MfG..an alle die noch investiert sind.

[frank55]

SAN DIEGO, Jun 12, 2001 /PRNewswire via COMTEX/ -- Nanogen, Inc. (Nasdaq: NGEN)
announced that today it has been awarded an additional United States Patent
relating to methods for using its electronic microarray technology for DNA
fingerprinting. U.S. Patent No. 6,245,508, entitled "Method of Fingerprinting
Utilizing an Electronically Addressable Array" (the "`508 patent"), is the
twenty-fourth U.S. patent issued to the Company. This patent further illustrates
the flexibility and applicability of Nanogen`s electronic microarray technology
to enhancing molecular biological procedures. This is Nanogen`s fifth patent to
issue in the last three months.

The `508 patent claims cover methods for DNA fingerprinting using electronically
addressable arrays. The claims describe improved methods for DNA fingerprinting
and analysis by applying electronic stringency control to manipulate DNA samples
and to electronically discriminate between varying lengths of DNA fragments.
This information can be useful in instances where the source of DNA is to be
determined, such as in paternity and forensic analyses.

Ron Sosnowski, Ph.D., Nanogen`s Director of Molecular Biology and co-inventor on
the `508 patent, stated, "The claims of the `508 describe the direct use of an
electric field to discriminate DNA fragments according to length. This is a
further demonstration of the unique capability of electric fields in controlling
DNA hybridization processes."

Kieran T. Gallahue, President of Nanogen, commented, "We are very pleased with
the rapid expansion of our patent portfolio. The `508 patent represents another
example of an important application that is enhanced and improved through the
integration of electronic control. Nanogen continues to invest in technology
developments that will integrate the power of electronics with customer-valued
applications."

Nanogen markets its NanoChip(TM) Molecular Biology Workstation system to
scientists and genomics laboratories, setting new standards for SNP scoring. In
addition, Nanogen is developing a series of electronics-based products to help
researchers and clinical healthcare providers accelerate their practical
understanding and use of genomic information. The products introduced and under
development are intended to provide quick and accurate analysis of DNA, RNA and
proteins, and may eventually "bridge" the gap between the research and clinical
settings. The Nanogen system is intended for research use only and not for use
in diagnostic procedures. For additional information please visit Nanogen`s web
site at www.nanogen.com.

This press release contains forward-looking statements that are subject to risks
and uncertainties that could cause actual results to differ materially from
those set forth in the forward-looking statements, including whether the
Company`s NanoChip(TM) system can be successfully commercialized, whether
products under development can be successfully developed and commercialized,
whether the patented inventions can be successfully incorporated into commercial
products, whether results reported by our customers or partners can be
identically replicated, whether the Company`s collaborations will continue to be
funded, and other risks and uncertainties discussed under the caption "Factors
That May Affect Results" and elsewhere in the Company`s Form 10-K for the year
ended December 31, 2000 filed with the Securities and Exchange Commission. These
forward-looking statements speak only as of the date hereof. The Company
disclaims any intent or obligation to update these forward-looking statements.